«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:

26卷

期数:

2020年05期

页码:

450-453

栏目:

临床医学

出版日期:

2020-09-20

文章信息/Info

Title:

The effect of mutations in TGF-β/ SMAD4 signal pathway on the survival of patients with pancreatic cancer

文章编号:

1006-8147(2020)05-0450-04

作者:

方闯; 田伟军

（天津医科大学总医院普通外科，天津 300052）

Author(s):

FANG Chuang; TIAN Wei-jun

（Department of General Surgery, General Hospital, Tianjin Medical University, Tianjin 300052, China）

关键词:

胰腺癌; 基因突变; 生存分析; TGF-β/SMAD4信号通路

Keywords:

pancreatic cancer;  gene mutation;  survival analysis;  TGF- β/SMAD4 signaling pathway

分类号:

R735.9

DOI:

-

文献标志码:

A

摘要:

目的：分析胰腺导管腺癌患者转化生长因子（TGF）-β/SMAD4信号通路中基因突变的情况及对生存的影响。方法：回顾性分析天津医科大学总医院普通外科2016年7月—2019年9月共19例胰腺导 管腺癌患者的临床资料，NGS检测患者基因突变情况，查询dbSNP及COSMIC数据库关键基因突变位点的临床意义。结果：19例胰腺导管腺癌患者中最常见的基因突变是 KRAS（84.2%）、TP53（68.4%）、 SMAD4（26.3%）、CDKN2A（26.3%）、CREBBP（15.8%）、RNF43（15.8%）、BRAF（15.8%）等。具有TGF-β/SMAD4信号通路相关基因突变的患者有7例（36.8%），其中SMAD4基因突变组中位生存时间5.0个 月，无SMAD4基因突变组中位生存时间14.0个月，差异有统计学意义（P=0.032）。结论： TGF-β/SMAD4信号通路中具有SMAD4基因突变患者的临床预后相较于无基因突变患者的临床预后更差，此通路中 具有多个基因突变其预后相对更差。

Abstract:

Objective: To analyze the status of gene mutations in transforming growth factor(TGF)-β/SMAD4 signal pathway in patients with pancreatic cancer and its effect on survival. Methods: The clinical data of 19 patients with pancreatic cancer from July 2016 to September 2019 in the General Hospital of Tianjin Medical University were analyzed retrospectively, the gene mutations were detected by NGS and the clinical significance of querying the key gene mutation sites in dbSNP and COSMIC databases were investigated. Results: The most common gene mutations in 19 patients with pancreatic cancer were KRAS(84.2%), TP53(68.4%), SMAD4(26.3%), CDKN2A(26.3%), CREBBP(15.8%), RNF43(15.8%), BRAF (15.8%), etc. There were 7(36.8%) patients with the TGF-β/ SMAD4 signal pathway-related gene mutations. The median survival time of the SMAD4 gene mutation group is 5.0 months, and the median survival time in the non-SMAD4 gene mutation group is 14.0 months, and the difference was statistically significant(P=0.032). Conclusion: The clinical prognosis of patients with the SMAD4 gene mutation in TGF-β/SMAD4 signaling pathway is worse than that of patients without gene mutations, and the prognosis of patients with multiple gene mutations in this pathway is relatively worse.

参考文献/References:

[1] Saad A M, Turk T, AI-Husseini M J, et al. Trends in pancreatic adenocarcinoma incidence and mortality in the united states in the last four decades; a seer-based study [J]. BMC Cancer, 2018,18(1):688
[2] Rahib L, Smith B D, Aizenberg R, et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States [J]. Cancer Res, 2014, 74(11):2931
[3] Chen W, Zheng R, Baade P D, et al. Cancer statistics in China, 2015[J]. Ca A Cancer J Clin, 2016,66(2):115
[4] Howlader N, Noone A M, Krapcho M, et al. SEER cancer statistics review 1975-2009(vintage 2009 populations)[C]. USA: Surveillance Research Program of the National Cancer Institute, 2012
[5] Conroy T, Paillot B, Francois E, et al. Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer-a groupe tumeurs digestives of the federation nationale des centres de lutte contre le cancer study [J]. J Clin Oncol, 2004,23(6):1228
[6] Von Hoff D D, Ervin T, Arena F P, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine[J]. N Engl J Med, 2013,369(18):1691
[7] Jones S, Zhang X, Parsons D W, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses[J]. Science, 2008,321(5897):1801
[8] Waddell N, Pajic M, Patch A, et al. Whole genomes redefine the mutational landscape of pancreatic cancer[J]. Nature, 2015,518(7540):495
[9] Dreyer S B, Chang D K, Bailey P, et al. Pancreatic cancer genomes: implications for clinical management and therapeutic development [J]. Clin Cancer Res, 2017,23(7):1638
[10] Bournet B, Buscail C, Muscari F, et al. Targeting kras for diagnosis, prognosis, and treatment of pancreatic cancer: hopes and realities[J]. Eur J Cancer, 2016,54(1):75
[11] Fang Y, Yao Q, Chen Z, et al. Genetic and molecular alterations in pancreatic cancer implications for personalized medicine[J]. Med Sci Monit, 2013,19(1):916
[12] Zhao M, Mishra L, Deng C. The role of TGF-β/SMAD4 signaling in cancer [J]. Int J of Biol Sci, 2018,14(2):111
[13] Cox A D, Fesik S W, Kimmelman A C, et al. Drugging the undruggable ras: mission possible? [J] .Nat Rev Drug Discov, 2014,13(11):828
[14] Khoo K H, Verma C S, Lane D P. Drugging the p53 pathway: understanding the route to clinical efficacy[J]. Nat Rev Drug Discov, 2014, 13(3):217
[15] Schutte M, Hruban R H, Geradts J, et al. Abrogation of the Rb/p16 tmor-suppressive pathway in virtually all pancreatic carcinomas[J]. Cancer Res,1997,57(15):3126
[16] 程时丹. SMAD4与消化系肿瘤[J]. 胃肠病学和肝病学杂志, 2006, 15(3):323
[17] Kojima K, Vickers S M, Adsay N V, et al. Inactivation of smad4 accelerates krasG12D-mediated pancreatic neoplasia[J]. Cancer Res, 2007,67(17):8121
[18] Hua Z, Zhang Y C, Hu X M, et al. Loss of DPC4 expression and its correlation with clinicopathological parameters in pancreatic carcinoma[J]. World J Gastroenterol, 2003,9(12):2764
[19] Fullerton P T, Creighton C J, Matzuk M M. Insights into SMAD4 loss in pancreatic cancer from inducible restoration of TGF-B signaling[J].Mol Endocrinol, 2015,29(10):1440
[20] Herman J M, Jabbour S K, Lin S H, et al. Smad4 loss correlates with higher rates of local and distant failure in pancreatic adenocarcinoma patients receiving adjuvant chemoradiation[J]. Pancreas, 2018, 47(2):208

相似文献/References:

[1]赵青春,韦 森,张洪兵,等.分析第6版和第7版TNM分期在肺腺癌患者中的差异[J].天津医科大学学报,2015,21(05):432.
[2]李辰运,孙 彤,卓 娜,等.胰腺导管腺癌中腺苷酸激酶4 的表达及临床意义[J].天津医科大学学报,2018,24(01):43.
　LI Chen-yun,SUN Tong,ZHUO Na,et al.Expression of AK4 in pancreatic ductal carcinoma and its clinical significance[J].Journal of Tianjin Medical University,2018,24(05):43.
[3]余 冬,冯 霜,李 俊,等.MiR-199a-3p在胰腺癌中的表达水平及生物信息学分析[J].天津医科大学学报,2019,25(02):119.
　YU Dong,FENG Shuang,LI Jun,et al.The expression of miR-199a-3p in pancreatic cancer and bioinformatics analysis[J].Journal of Tianjin Medical University,2019,25(05):119.
[4]王 艳,郭 志,杨雪玲,等.CT引导下125I粒子植入对缓解胰腺癌疼痛的疗效观察[J].天津医科大学学报,2019,25(02):132.
　WANG Yan,GUO Zhi,YANG Xue-ling,et al.CT-guided iodine-125 seeds implantation therapy for pancreatic cancer patients with pain[J].Journal of Tianjin Medical University,2019,25(05):132.
[5]王雨婷,刘 朔,王 茜,等.儿童Gitelman综合征2例临床特点及基因分析[J].天津医科大学学报,2019,25(05):536.
[6]魏莹,刘戈力,郑荣秀,等.Alstrom综合征1例报告及文献复习[J].天津医科大学学报,2020,26(06):572.
[7]刘笑孝,王宇,褚亚男,等.X连锁低磷性佝偻病一家系报告并文献复习[J].天津医科大学学报,2021,27(04):419.
[8]蒋海燕,赵悦,郑荣秀.姐弟同患肝豆状核变性病例报道[J].天津医科大学学报,2022,28(04):442.
[9]周 彤,赵 倩.整合多组学数据筛选胰腺癌进展中的关键基因[J].天津医科大学学报,2024,30(02):132.[doi:10.20135/j.issn.1006-8147.2024.02.0132]
　ZHOU Tong,ZHAO Qian.Integrating multi-omics data to screen key genes in pancreatic cancer progression[J].Journal of Tianjin Medical University,2024,30(05):132.[doi:10.20135/j.issn.1006-8147.2024.02.0132]

备注/Memo

备注/Memo:

作者简介 方闯（1993-），男，硕士在读，研究方向：普外科；
通信作者：田伟军，E-mail： jonathontian@163.com。

常用功能

更新日期/Last Update: 2020-09-18